Clinical trials: Acute Infectious Diseases
Coronavirus Infection, Severe Acute Respiratory Syndrome
COVID-19 Seroprevalence Study in French Guiana
Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.
- Conditions
- Coronavirus Infection, Severe Acute Respiratory Syndrome, SARS-CoV Infection, Covid19
- Trial name
- EPI-COVID-POP (NCT04490850)
- Testing
- Blood sample
- Where
- 5 sites in French Guiana
- Volunteers
- 3,541 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Acute Otitis Media
A Phase II Study of an Otic Formulation in Treating Peri-Operative Tube Otorrhea
The purpose of this study is to determine if an otic formulation is safe and effective in treating peri-operative tube otorrhea.
- Trial name
- NCT00578773
- Testing
- Moxidex otic solution, Moxifloxacin otic solution, Tympanostomy tubes
- Volunteers
- 303 people
- Sponsor
- Alcon Research
Post Acute COVID-19 Syndrome
Digital Health Intervention Based on Artificial Intelligence to Support the Personalized Recovery of Long COVID Patients Affected by Fatigue (AIDA)
The AIDA feasibility study builds upon mental health and technology acceptance theoretical frameworks. It examines the feasibility of a mobile-based digital program to support patients with long covid affected by fatigue.
- Trial name
- AIDA (NCT05483829)
- Testing
- Adhera® Fatigue for Long COVID program
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Adhera Health, Inc.
COVID-19
Safety and Immunogenicity Study of EgyVax Vaccine Candidate for Prophylaxis of COVID-19 Infection
This is a phase I, prospective, three-arm, open-label, randomized, first in human (FIH) clinical trial to assess the safety and immunogenicity of EgyVax vaccine candidate for prophylaxis of SARS-CoV-2 infection (COVID-19).
- Trial name
- Sphinx (NCT05218070)
- Testing
- EgyVax Vaccine Candidate
- Where
- Egypt
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Eva Pharma
Sars-CoV-2 Infection
Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention
The investigated product is a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Booster Vaccine candidate optimized for the Omicron/BA.2 variant.
- Trial name
- NCT05844202
- Testing
- Alveavax-v1.2, Janssen Ad26.COV2.S
- Where
- 8 sites in South Africa
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Alvea Holdings, LLC
COVID-19, Coronavirus Disease 2019
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza
The main purpose of this study is to understand: the symptoms of COVID-19 or influenza- health-related outcomes of people with COVID-19 or influenza (influenza only included in updated study analyses) the potential effects of…
- Conditions
- COVID-19, Coronavirus Disease 2019, Influenza
- Trial name
- NCT05160636
- Testing
- COVID-19 Vaccine
- Where
- United States
- Volunteers
- 999 people
- Sponsor
- Pfizer
Influenza, Acute Respiratory Infection
Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza
Influenza and other acute respiratory viral infections remain practically uncontrollable diseases due to the high variability of the antigenic structure of influenza viruses and the heterogeneity of pathogens of acute respiratory…
- Trial name
- NCT06183229
- Testing
- Cycloferon
- Where
- 2 sites in Russia
- Volunteers
- 166 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Common Cold, Acute Respiratory Infection
Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection
Study to assess the efficacy and safety of XC8, film-coated tablets, 10 mg in comparison with placebo in patients with dry non-productive cough against acute respiratory infection.
- Conditions
- Common Cold, Acute Respiratory Infection, Influenza, Human
- Trial name
- NCT05273619
- Testing
- XC8, film-coated tablets, 10 mg
- Where
- 6 sites in Russia
- Volunteers
- 250 people
- Sponsor
- Valenta Pharm JSC
Hepatic Failure, Liver Failure
Cardiox Liver Function Test Pivotal Trial
Performance evaluation of LFT Dye Monitor System using ICG - plasma disappearance rate value (PDR) to assess liver function in normal patients as well as in patients with mild to severe hepatic impairment compared to manual Serum…
- Trial name
- LFT-0002 (NCT02552901)
- Testing
- 0.1 mg/kg ICG Dose, 0.5 mg/kg ICG dose
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Cardiox Corporation
Covid19, SARS-CoV Infection
An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers
The BBV152 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- NCT04641481
- Testing
- BBV152
- Where
- India
- Volunteers
- 25,800 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
Acute Otitis Media
Safety and Efficacy of Moxidex Otic
The purpose of this study is to determine if Moxidex otic solution is safe and effective in treating middle ear infections in patients with ear tubes.
- Trial name
- NCT01071902
- Testing
- Moxidex otic solution, Moxifloxacin otic solution, Vehicle
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Alcon Research
Otitis Media
Levofloxacin In The Treatment Of Children With Recurrent And/or Persistent Acute Otitis Media
The purpose of this study is to demonstrate non-inferiority of levofloxacin compared with amoxicillin/clavulanate on the clinical response at the end of therapy in infants and children who have recurrent and/or persistent acute…
- Trial name
- NCT00051753
- Testing
- levofloxacin; amoxicillin/clavulanate
- Volunteers
- 1,643 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Influenza, Human, Acute Respiratory Infection
Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections
The purpose of the study was to evaluate efficacy of prophylactic Ingavirin intake by people having contact with sick people infected with influenza and other acute respiratory viral infections
- Conditions
- Influenza, Human, Acute Respiratory Infection, Common Cold, Flu
- Trial name
- NCT03189537
- Testing
- Ingavirin (Imidazolyl Ethanamide Pentandioic Acid)
- Where
- 2 sites in Russia
- Volunteers
- 400 people
- Sponsor
- Valenta Pharm JSC
COVID 19 Disease, Mild to Moderate COVID 19 Disease
A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression
A clinical study to assess the efficacy and safety of oral tafenoquine compared to placebo in patients with mild to moderate COVID 19 disease and low risk of disease progression (the "ACLR8-LR" study).
- Conditions
- COVID 19 Disease, Mild to Moderate COVID 19 Disease, SARS-CoV-2, Infectious Disease
- Trial name
- NCT05947812
- Testing
- Tafenoquine Oral Tablet
- Volunteers
- 148 people
- Sponsor
- 60P Australia Pty Ltd
Upper Resp Tract Infection
TEM-PCR™ Prospective Clinical Utility Study
This is a randomized, open-label, multi-center, prospective study to assess the clinical utility of the TEM-PCR Upper Respiratory Infection (URI) Panel in adult subjects age 65 and older presenting to the primary care clinic with…
- Trial name
- NCT04248361
- Testing
- TEM-PCR URI Panel, SOC/Empiric Diagnosis
- Where
- 4 sites in United States
- Volunteers
- 314 people
- Sponsor
- Diatherix Laboratories, LLC
ARDS Due to COVID-19
Surfactant-BL in Adult Acute Respiratory Distress Syndrome Due to COVID-19
The purpose of this study is to prove the efficacy and safety Surfactant-BL, administered by inhalation in adult hospitalized patients with ARDS due to COVID-19.
- Trial name
- NCT04568018
- Testing
- Surfactant
- Where
- Russia
- Volunteers
- 120 people
- Sponsor
- Biosurf LLC.
Infections, Urinary Tract
GSK2251052 in Complicated Urinary Tract Infection
This study is being conducted to evaluate the safety, efficacy (clinical and microbiological), pharmacokinetics/pharmacodynamics of GSK2251052 and to assess whether it would be a suitable antibiotic for the treatment for febrile…
- Trial name
- NCT01381549
- Testing
- GSK2251052, imipenem-cilastatin
- Where
- 24 sites in United States, Canada and 4 more
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Otitis Externa, Otorhinolaryngologic Diseases
Safety and Efficacy Study of Foam Otic Cipro Compared to a Standard Solution ( Ciloxan - Alcon Labs ) to Treat Acute Otitis Externa
The purpose of this study is to assess the Safety and Efficacy of Foam Otic Cipro, a novel medication developed to treat Acute Diffuse Otitis Externa of bacterial origin.
- Conditions
- Otitis Externa, Otorhinolaryngologic Diseases, Ear Diseases, Otitis
- Trial name
- NCT00872209
- Testing
- 0.3% Ciprofloxacin Ear Drops, 0.3% Ciprofloxacin Foam Otic Cipro
- Where
- 4 sites in Israel
- Volunteers
- 100 people
- Sponsor
- Otic Pharma
Urinary Tract Infections, Acute Pyelonephritis
Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis
The primary objective of this study is to evaluate the microbiological and clinical outcome of treatment with finafloxacin for 5 days versus finafloxacin for 10 days versus ciprofloxacin for 10 days as a reference comparator.
- Trial name
- NCT01928433
- Testing
- Finafloxacin 800 mg i.v. once daily, Finafloxacin 800 mg tablets once daily, Ciprofloxacin 400 mg i.v. twice daily
- Where
- Germany
- Volunteers
- 225 people
- Sponsor
- MerLion Pharmaceuticals GmbH
COVID-19, SARS-CoV2 Infection
COVAG - Covid-19 Antigen Study - the Diagnostic Efficacy of SARS-CoV-2 Rapid Detection Tests
The aim of the COVAG study (Covid-19 Antigen study) is to assess the diagnostic efficacy of two of the most used rapid antigen tests (Roche \& Abbott).
- Conditions
- COVID-19, SARS-CoV2 Infection, SARS (Disease)
- Trial name
- COVAG (NCT05074017)
- Testing
- 3 nasopharyngeal swab
- Where
- 2 sites in Germany
- Volunteers
- 2,222 people, healthy volunteers welcome
- Sponsor
- Synlab Holding Deutschland GmbH